OptimizeRx posts Q3 net income of $0.8M, revenue up 22% to $26.1M; raises FY2025 outlook

OptimizeRx Corp

2025-Q3 EPS reported $0.01 vs consensus $0.05 ▼ miss (-77.9%)

Q3 revenue $26.1M (+22% YoY); GAAP net income $0.8M ($0.04/share) vs loss of $9.1M in Q3 2024.
Adjusted EBITDA $5.1M (up from $2.7M); gross profit $17.5M (+30% YoY).
Raised FY2025 guidance: revenue $105-109M, adjusted EBITDA $16-19M.
Introduced FY2026 guidance: revenue $118-124M, adjusted EBITDA $19-22M.
Cash $19.5M at Sep 30, 2025; paid $2M on term loan post-quarter.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.